Skip to main content
. 2012 Aug 16;2:584. doi: 10.1038/srep00584

Figure 3. Knockdown of CBX5 with sh-RNAi in vitro.

Figure 3

(a) Western blot of knockdown of CBX5 in lung CD133+-TSLCs derived from two patients (No.1&2). The abilities of (b) sphere formation, (c) colony formation, and (d) migration in CD133+-TSLCs treated with sh-CBX5 RNAi were decreased. The percentages of (e–f) CD133+-TSLCs and (g) SP cells were significantly reduced. (h) Using RT-PCR, we measured suppression of expression levels of BIRC5, SMAD1, MSH2, DNMT1, E2F1, RB1, TAF5, ESR1, MLH1, and SIN3A in the sh-CBX5 RNAi treated lung CD133+-TSLCs. These genes were identified by statistically significant correlation with CBX5 in lung cancer survival analysis. All data shown are the mean ± SD of 3 experiments. (*P < 0.05)